Trial Profile
DYSPORT for Injection AbobotulinumtoxinA Neurotoxin Clinical and Health Economics Outcomes Registry in Cervical Dystonia (ANCHOR-CD)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2020
Price :
$35
*
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Torticollis
- Focus Therapeutic Use
- Acronyms ANCHOR-CD
- Sponsors Ipsen
- 16 Sep 2020 Results of metaanalysis of three observational studies (INTEREST IN CD1, INTEREST IN CD2 and ANCHOR CD) evaluating the effect of abobotulinumtoxinA on pain associated with cervical dystonia presented at the 24th International Congress of Parkinson's Disease and Movement Disorders
- 09 Oct 2018 Results from INTEREST IN CD1 [NCT00833196] INTER- EST IN CD2 [NCT01753349] and ANCHOR-CD [NCT01314365] describing the use of injection guidance (at baseline/ first injection visit and at 1 year) in 585 subjects, presented at the 22nd International Congress of Parkinson's Disease and Movement Disorders.
- 09 Oct 2018 Results from INTEREST IN CD1 [NCT00833196] INTER- EST IN CD2 [NCT01753349] and ANCHOR-CD [NCT01314365] describing the patterns of Cervical dystonia and injection parameters in subjects routinely treated with aboBoNT-A over 1 year (N=585), presented at the 22nd International Congress of Parkinson's Disease and Movement Disorders.